selexipag and Dyspnea

selexipag has been researched along with Dyspnea* in 2 studies

Trials

1 trial(s) available for selexipag and Dyspnea

ArticleYear
Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.
    The European respiratory journal, 2022, Volume: 60, Issue:1

    Treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remain limited. Selexipag, an oral selective IP prostacyclin receptor agonist approved for pulmonary arterial hypertension, is a potential treatment option for CTEPH.. In this multicentre, randomised, double-blind, placebo-controlled study, 78 Japanese patients with inoperable CTEPH or persistent/recurrent pulmonary hypertension after pulmonary endarterectomy and/or balloon pulmonary angioplasty were randomly assigned to receive placebo or selexipag. The primary end-point was the change in pulmonary vascular resistance (PVR) from baseline to week 20. Secondary end-points were changes in other haemodynamic parameters: 6-min walk distance (6MWD), Borg dyspnoea scale score, World Health Organization (WHO) functional class, EuroQol five-dimension five-level tool and N-terminal pro-brain natriuretic peptide.. The change in PVR was -98.2±111.3 dyn·s·cm. Selexipag significantly improved PVR and other haemodynamic variables in patients with CTEPH, although exercise capacity remained unchanged. Further large-scale investigation is necessary to prove the role of selexipag in CTEPH.

    Topics: Acetamides; Antihypertensive Agents; Chronic Disease; Dyspnea; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Pyrazines; Treatment Outcome

2022

Other Studies

1 other study(ies) available for selexipag and Dyspnea

ArticleYear
Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension without Symptoms in BMPR2 Mutation Carriers: Cautionary Tales?
    American journal of respiratory and critical care medicine, 2020, 12-01, Volume: 202, Issue:11

    Topics: Acetamides; Adolescent; Antihypertensive Agents; Asymptomatic Diseases; Bone Morphogenetic Protein Receptors, Type II; Cardiac Catheterization; Disease Progression; Dyspnea; Echocardiography; Exercise Tolerance; Female; Genetic Testing; Heterozygote; Humans; Male; Phenylpropionates; Pulmonary Arterial Hypertension; Pyrazines; Pyridazines; Sildenafil Citrate; Syncope; Vasodilator Agents

2020